Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L de Vos

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatmentAnne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
Neuropathology and Applied Neurobiology|February 20, 2020
Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support toolL P Priesterbach-Ackley, H B Boldt, J K Petersen, et al.
Journal of Neuro-Oncology|October 15, 2025
Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort studyLaura van den Berg, Joyce Wilbers, Filip Y F L de Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2015
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trialLinda Dirven, Martin J van den Bent, Andrew Bottomley, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2026
BRAF<sup>V600E</sup>-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery ProtocolSoemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, et al.
Optics Express|June 24, 2016
Optical and radiometric models of the NOMAD instrument part II: the infrared channels - SO and LNOI R Thomas, A C Vandaele, S Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
British Journal of Cancer|March 10, 2020
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancerRobin M J M van Geel, Emilie M J van Brummelen, Ferry A L M Eskens, et al.
Plos One|February 9, 2026
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG)A M de Jong, A T J van der Boog, C C B Post, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatmentAnne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
Neuropathology and Applied Neurobiology|February 20, 2020
Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support toolL P Priesterbach-Ackley, H B Boldt, J K Petersen, et al.
Journal of Neuro-Oncology|October 15, 2025
Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort studyLaura van den Berg, Joyce Wilbers, Filip Y F L de Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2015
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trialLinda Dirven, Martin J van den Bent, Andrew Bottomley, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2026
BRAF<sup>V600E</sup>-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery ProtocolSoemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, et al.
Optics Express|June 24, 2016
Optical and radiometric models of the NOMAD instrument part II: the infrared channels - SO and LNOI R Thomas, A C Vandaele, S Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
British Journal of Cancer|March 10, 2020
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancerRobin M J M van Geel, Emilie M J van Brummelen, Ferry A L M Eskens, et al.
Plos One|February 9, 2026
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG)A M de Jong, A T J van der Boog, C C B Post, et al.
Pageof 11